Uptake of free and DNA-bound daunorubicin and doxorubicin into human leukemic cells
- PMID: 498420
- DOI: 10.1007/BF00253105
Uptake of free and DNA-bound daunorubicin and doxorubicin into human leukemic cells
Abstract
Leukemic cells from seven patients with acute nonlymphoblastic leukemia and granulocytes, and mononuclear cells from three healthy controls were isolated by centrifugation on metrozoate-dextran. The intracellular accumulation of both the free and DNA-bound forms of daunorubicin and doxorubicin was studied in vitro. The uptake of unbound daunorubicin was higher than that of doxorubicin. At drug concentrations of 1.75 microM and higher the uptake of the free drugs was greater than that of the bound forms, but at lower drug concentrations the uptake was about the same. This could at least partly be explained by a greater dissociation of the DNA-drug complexes at lower drug concentrations. The uptake into normal leukocytes was of the same order of magnitude as that into leukemic cells. There was a great interindividual variation in the accumulation of both free and DNA-bound drugs in the cells from leukemic patients. This variation might be of importance for the prediction of individual sensitivity to the different drugs.
Similar articles
-
Pharmacokinetics of daunorubicin and doxorubicin in plasma and leukemic cells from patients with acute nonlymphoblastic leukemia.Ther Drug Monit. 1989;11(2):140-8. doi: 10.1097/00007691-198903000-00004. Ther Drug Monit. 1989. PMID: 2718219
-
Analysis of heterogeneity in daunorubicin uptake by human leukemia cells using laser flow cytometry.Invest New Drugs. 1985;3(3):273-7. doi: 10.1007/BF00179431. Invest New Drugs. 1985. PMID: 3864764
-
DNA-binding parameters of daunorubicin and doxorubicin in the conditions used for studying the interaction of anthracycline-DNA complexes with cells in vitro.Cancer Chemother Pharmacol. 1979;2(1):7-10. doi: 10.1007/BF00253097. Cancer Chemother Pharmacol. 1979. PMID: 498422
-
Comparative study in mice of the toxicity, pharmacology, and therapeutic activity of daunorubicin-DNA and doxorubicin-DNA complexes.Cancer Chemother Pharmacol. 1979;2(1):25-30. doi: 10.1007/BF00253101. Cancer Chemother Pharmacol. 1979. PMID: 498415
-
Biochemistry of normal and leukemic leucocytes, thrombocytes, and bone marrow cells.Adv Cancer Res. 1965;9:303-410. doi: 10.1016/s0065-230x(08)60449-2. Adv Cancer Res. 1965. PMID: 5322430 Review. No abstract available.
Cited by
-
Intracellular concentrations of anti cancer drugs in leukemic cells in vitro vs in vivo.Cancer Chemother Pharmacol. 1990;25(4):252-6. doi: 10.1007/BF00684881. Cancer Chemother Pharmacol. 1990. PMID: 2295112
-
Uptake, metabolism, and cytotoxicity of doxorubicin in human Ewing's sarcoma and rhabdomyosarcoma cells.Cancer Chemother Pharmacol. 1984;12(1):59-63. doi: 10.1007/BF00255912. Cancer Chemother Pharmacol. 1984. PMID: 6690077
-
Comparison of the intracellular pharmacokinetics of doxorubicin and 4'-epi-doxorubicin in patients with acute leukemia.Cancer Chemother Pharmacol. 1989;24(4):225-9. doi: 10.1007/BF00257622. Cancer Chemother Pharmacol. 1989. PMID: 2752502
-
Uptake of the daunorubicin-DNA complex in cultured fibroblasts.Cancer Chemother Pharmacol. 1979;2(1):3-6. doi: 10.1007/BF00253096. Cancer Chemother Pharmacol. 1979. PMID: 498416
-
Intracellular uptake and cytotoxic effect in vitro of doxorubicin and epirubicin in human leukemic and normal hematopoietic cells.Cancer Chemother Pharmacol. 1991;29(1):7-12. doi: 10.1007/BF00686328. Cancer Chemother Pharmacol. 1991. PMID: 1742852